| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 48 | 2021 | 1133 | 1.720 |
Why?
|
| Lung Neoplasms | 56 | 2023 | 2365 | 1.540 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 43 | 2021 | 2544 | 1.090 |
Why?
|
| Advisory Committees | 1 | 2022 | 90 | 0.730 |
Why?
|
| Medical Oncology | 1 | 2022 | 404 | 0.570 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 3 | 2009 | 12 | 0.570 |
Why?
|
| Vinblastine | 13 | 2002 | 85 | 0.510 |
Why?
|
| Paclitaxel | 15 | 2008 | 479 | 0.480 |
Why?
|
| Ifosfamide | 12 | 2003 | 37 | 0.410 |
Why?
|
| Combined Modality Therapy | 26 | 2010 | 1723 | 0.370 |
Why?
|
| Adenocarcinoma | 12 | 2016 | 1173 | 0.360 |
Why?
|
| Esophageal Neoplasms | 7 | 2010 | 344 | 0.350 |
Why?
|
| Survival Rate | 22 | 2021 | 1948 | 0.310 |
Why?
|
| Antineoplastic Agents | 12 | 2019 | 2303 | 0.310 |
Why?
|
| Carcinoma, Squamous Cell | 9 | 2019 | 1077 | 0.310 |
Why?
|
| Cisplatin | 15 | 2010 | 568 | 0.310 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 13 | 2008 | 158 | 0.280 |
Why?
|
| Antineoplastic Agents, Phytogenic | 8 | 2008 | 270 | 0.270 |
Why?
|
| Neoplasm Staging | 22 | 2019 | 2017 | 0.260 |
Why?
|
| Camptothecin | 4 | 2008 | 196 | 0.260 |
Why?
|
| Aged | 53 | 2021 | 20430 | 0.250 |
Why?
|
| Nucleosides | 1 | 2006 | 20 | 0.240 |
Why?
|
| Biomarkers, Tumor | 4 | 2023 | 1660 | 0.230 |
Why?
|
| Middle Aged | 55 | 2021 | 27569 | 0.220 |
Why?
|
| Carcinoma, Small Cell | 3 | 2004 | 115 | 0.210 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2020 | 244 | 0.210 |
Why?
|
| Radiosurgery | 2 | 2021 | 317 | 0.200 |
Why?
|
| Humans | 74 | 2023 | 93511 | 0.200 |
Why?
|
| Female | 60 | 2021 | 48698 | 0.180 |
Why?
|
| Male | 58 | 2021 | 44553 | 0.180 |
Why?
|
| Adult | 48 | 2021 | 27918 | 0.180 |
Why?
|
| United States Food and Drug Administration | 1 | 2022 | 142 | 0.180 |
Why?
|
| Taxoids | 7 | 2012 | 126 | 0.170 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 49 | 0.170 |
Why?
|
| Carboplatin | 8 | 2008 | 322 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 106 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2008 | 1914 | 0.170 |
Why?
|
| Salvage Therapy | 2 | 2019 | 235 | 0.160 |
Why?
|
| Capecitabine | 1 | 2020 | 97 | 0.150 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 1998 | 134 | 0.150 |
Why?
|
| Follow-Up Studies | 10 | 2021 | 3828 | 0.150 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 19 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2021 | 636 | 0.150 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2019 | 23 | 0.150 |
Why?
|
| Precision Medicine | 2 | 2016 | 456 | 0.150 |
Why?
|
| Remission Induction | 10 | 2011 | 738 | 0.150 |
Why?
|
| Infusions, Intravenous | 5 | 2002 | 401 | 0.150 |
Why?
|
| Aged, 80 and over | 15 | 2021 | 7061 | 0.140 |
Why?
|
| Pyrazoles | 1 | 2019 | 150 | 0.140 |
Why?
|
| Benzamides | 1 | 2019 | 246 | 0.140 |
Why?
|
| Treatment Outcome | 17 | 2014 | 9098 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 202 | 0.140 |
Why?
|
| Blood Group Incompatibility | 2 | 2009 | 22 | 0.130 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2015 | 86 | 0.130 |
Why?
|
| Piperazines | 1 | 2019 | 284 | 0.130 |
Why?
|
| Stomach Neoplasms | 2 | 2010 | 308 | 0.130 |
Why?
|
| Pneumonectomy | 4 | 2011 | 217 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2012 | 1448 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2012 | 603 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2021 | 761 | 0.120 |
Why?
|
| Prognosis | 9 | 2021 | 3910 | 0.120 |
Why?
|
| Interferon-alpha | 4 | 1997 | 187 | 0.110 |
Why?
|
| Carcinoma | 1 | 1998 | 439 | 0.110 |
Why?
|
| Fluorouracil | 9 | 1998 | 524 | 0.110 |
Why?
|
| Breast Neoplasms | 3 | 2020 | 3110 | 0.110 |
Why?
|
| Radiotherapy, Image-Guided | 2 | 2012 | 62 | 0.110 |
Why?
|
| Mesna | 2 | 2008 | 8 | 0.100 |
Why?
|
| Disease Progression | 6 | 2023 | 1531 | 0.100 |
Why?
|
| Drug Administration Schedule | 12 | 2003 | 829 | 0.100 |
Why?
|
| Exanthema | 1 | 2014 | 39 | 0.100 |
Why?
|
| Blood Proteins | 1 | 2014 | 145 | 0.100 |
Why?
|
| Leucovorin | 8 | 1998 | 200 | 0.100 |
Why?
|
| Neoplasm Metastasis | 4 | 2012 | 1061 | 0.100 |
Why?
|
| Organoplatinum Compounds | 2 | 2004 | 91 | 0.090 |
Why?
|
| Ketones | 1 | 2012 | 14 | 0.090 |
Why?
|
| Furans | 1 | 2012 | 19 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2016 | 565 | 0.090 |
Why?
|
| Carcinoma, Large Cell | 1 | 2012 | 37 | 0.090 |
Why?
|
| Glutamates | 2 | 2014 | 84 | 0.090 |
Why?
|
| Proteomics | 1 | 2014 | 264 | 0.090 |
Why?
|
| Guanine | 2 | 2014 | 194 | 0.080 |
Why?
|
| Sirolimus | 1 | 2012 | 176 | 0.080 |
Why?
|
| United States | 2 | 2022 | 7619 | 0.080 |
Why?
|
| Recombinant Proteins | 6 | 2008 | 988 | 0.080 |
Why?
|
| Thigh | 1 | 1990 | 41 | 0.080 |
Why?
|
| ErbB Receptors | 4 | 2015 | 506 | 0.080 |
Why?
|
| Neutropenia | 6 | 2008 | 209 | 0.070 |
Why?
|
| Cladribine | 1 | 2009 | 29 | 0.070 |
Why?
|
| Disease-Free Survival | 5 | 2014 | 1170 | 0.070 |
Why?
|
| Transfusion Reaction | 1 | 2009 | 16 | 0.070 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1990 | 124 | 0.070 |
Why?
|
| Splenectomy | 1 | 2009 | 46 | 0.070 |
Why?
|
| Lymphocyte Subsets | 1 | 2009 | 69 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 78 | 0.070 |
Why?
|
| Transplantation | 1 | 2009 | 38 | 0.070 |
Why?
|
| Vidarabine | 1 | 2009 | 93 | 0.070 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2009 | 68 | 0.070 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2009 | 104 | 0.070 |
Why?
|
| Survival Analysis | 7 | 2011 | 1524 | 0.070 |
Why?
|
| Rituximab | 1 | 2009 | 128 | 0.070 |
Why?
|
| Erythropoietin | 1 | 2008 | 90 | 0.070 |
Why?
|
| Maximum Tolerated Dose | 5 | 2011 | 259 | 0.070 |
Why?
|
| Mutation | 5 | 2023 | 4272 | 0.070 |
Why?
|
| Drug Tolerance | 3 | 1996 | 59 | 0.070 |
Why?
|
| Quinazolines | 1 | 2008 | 211 | 0.060 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2009 | 289 | 0.060 |
Why?
|
| Transplantation, Homologous | 1 | 2009 | 1014 | 0.060 |
Why?
|
| Venous Thromboembolism | 1 | 2009 | 168 | 0.060 |
Why?
|
| Thoracic Neoplasms | 2 | 1998 | 65 | 0.060 |
Why?
|
| Area Under Curve | 2 | 2007 | 335 | 0.060 |
Why?
|
| Histocompatibility | 1 | 2006 | 66 | 0.060 |
Why?
|
| Drug Therapy | 1 | 2006 | 68 | 0.060 |
Why?
|
| Dacarbazine | 1 | 2006 | 100 | 0.060 |
Why?
|
| Filgrastim | 3 | 2008 | 56 | 0.060 |
Why?
|
| Radiotherapy Dosage | 4 | 2001 | 472 | 0.050 |
Why?
|
| Feasibility Studies | 4 | 2008 | 756 | 0.050 |
Why?
|
| Gene Amplification | 2 | 2019 | 140 | 0.050 |
Why?
|
| Neoplasms | 3 | 1997 | 3169 | 0.050 |
Why?
|
| Thionucleotides | 1 | 2004 | 54 | 0.050 |
Why?
|
| Brain Neoplasms | 2 | 2008 | 813 | 0.050 |
Why?
|
| Cephalexin | 1 | 2003 | 6 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2009 | 990 | 0.050 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2003 | 20 | 0.050 |
Why?
|
| Etoposide | 4 | 2008 | 204 | 0.050 |
Why?
|
| Survival | 1 | 2002 | 21 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2004 | 203 | 0.050 |
Why?
|
| Time Factors | 3 | 2014 | 5410 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 1395 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2009 | 939 | 0.040 |
Why?
|
| Hematologic Neoplasms | 1 | 2006 | 372 | 0.040 |
Why?
|
| Ipilimumab | 1 | 2021 | 63 | 0.040 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2001 | 34 | 0.040 |
Why?
|
| Pemetrexed | 2 | 2014 | 75 | 0.040 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.040 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 28 | 0.040 |
Why?
|
| Ceftizoxime | 1 | 1999 | 3 | 0.040 |
Why?
|
| Retrospective Studies | 6 | 2021 | 10164 | 0.040 |
Why?
|
| North America | 1 | 2000 | 195 | 0.040 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 1999 | 6 | 0.040 |
Why?
|
| Cephalosporins | 1 | 1999 | 25 | 0.040 |
Why?
|
| Thrombopoietin | 1 | 1999 | 12 | 0.040 |
Why?
|
| Megakaryocytes | 1 | 1999 | 38 | 0.040 |
Why?
|
| Biopsy | 1 | 2023 | 1175 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 537 | 0.040 |
Why?
|
| Europe | 1 | 2000 | 337 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2015 | 512 | 0.040 |
Why?
|
| Agranulocytosis | 2 | 1995 | 16 | 0.040 |
Why?
|
| Topotecan | 1 | 1998 | 46 | 0.030 |
Why?
|
| Macrolides | 2 | 2012 | 30 | 0.030 |
Why?
|
| Chemoradiotherapy | 2 | 2011 | 326 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2020 | 4560 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 836 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 1995 | 161 | 0.030 |
Why?
|
| Esophagus | 1 | 1998 | 113 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2009 | 2562 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 381 | 0.030 |
Why?
|
| Expectorants | 1 | 1996 | 5 | 0.030 |
Why?
|
| Chicago | 3 | 2014 | 1464 | 0.030 |
Why?
|
| International Agencies | 1 | 2015 | 34 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1996 | 97 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 1866 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1995 | 212 | 0.030 |
Why?
|
| Radiation Dosage | 2 | 2011 | 229 | 0.030 |
Why?
|
| Bone Marrow | 4 | 1998 | 409 | 0.030 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 1994 | 17 | 0.030 |
Why?
|
| Hydroxyurea | 4 | 1995 | 231 | 0.020 |
Why?
|
| Cetuximab | 1 | 2014 | 118 | 0.020 |
Why?
|
| Esophagitis | 3 | 1998 | 40 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 2012 | 504 | 0.020 |
Why?
|
| Ethers, Cyclic | 1 | 2012 | 8 | 0.020 |
Why?
|
| Indoles | 1 | 1994 | 303 | 0.020 |
Why?
|
| Bridged-Ring Compounds | 1 | 2012 | 16 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 2484 | 0.020 |
Why?
|
| Platinum | 1 | 2012 | 67 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 1780 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 876 | 0.020 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2011 | 17 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2015 | 1729 | 0.020 |
Why?
|
| Confidence Intervals | 2 | 2003 | 217 | 0.020 |
Why?
|
| Receptors, Growth Factor | 1 | 2011 | 52 | 0.020 |
Why?
|
| Administration, Oral | 3 | 2001 | 657 | 0.020 |
Why?
|
| Genes, ras | 1 | 2011 | 97 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2011 | 72 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2011 | 134 | 0.020 |
Why?
|
| Genomics | 1 | 2016 | 848 | 0.020 |
Why?
|
| Whole-Body Counting | 1 | 1989 | 4 | 0.020 |
Why?
|
| Gallium Radioisotopes | 1 | 1989 | 20 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2011 | 199 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 1713 | 0.020 |
Why?
|
| Darbepoetin alfa | 1 | 2008 | 5 | 0.020 |
Why?
|
| Cohort Studies | 3 | 2007 | 3054 | 0.020 |
Why?
|
| Hematinics | 1 | 2008 | 11 | 0.020 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2008 | 18 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 1001 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1989 | 281 | 0.020 |
Why?
|
| Risk Factors | 2 | 2014 | 5898 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1990 | 260 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2008 | 361 | 0.020 |
Why?
|
| Platinum Compounds | 1 | 2007 | 29 | 0.020 |
Why?
|
| Anemia | 1 | 2008 | 134 | 0.020 |
Why?
|
| Biomarkers | 1 | 2014 | 1910 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 759 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2008 | 373 | 0.020 |
Why?
|
| Cyclophosphamide | 3 | 1992 | 278 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 1261 | 0.010 |
Why?
|
| Leukemia | 1 | 1987 | 301 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2007 | 320 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2004 | 65 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2007 | 446 | 0.010 |
Why?
|
| Bryostatins | 1 | 2003 | 14 | 0.010 |
Why?
|
| Young Adult | 1 | 2015 | 6930 | 0.010 |
Why?
|
| Lactones | 1 | 2003 | 27 | 0.010 |
Why?
|
| Premedication | 1 | 2003 | 57 | 0.010 |
Why?
|
| Sex Factors | 2 | 2000 | 1105 | 0.010 |
Why?
|
| Smoking | 2 | 2000 | 648 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2003 | 276 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 2001 | 66 | 0.010 |
Why?
|
| Radiation Pneumonitis | 1 | 2001 | 23 | 0.010 |
Why?
|
| Lung | 1 | 1987 | 1366 | 0.010 |
Why?
|
| Clinical Trials as Topic | 2 | 1998 | 1103 | 0.010 |
Why?
|
| Methotrexate | 2 | 1992 | 225 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2003 | 362 | 0.010 |
Why?
|
| Doxorubicin | 2 | 1992 | 284 | 0.010 |
Why?
|
| Drug Evaluation | 2 | 1990 | 109 | 0.010 |
Why?
|
| Creatinine | 1 | 2001 | 293 | 0.010 |
Why?
|
| Spirometry | 1 | 2000 | 77 | 0.010 |
Why?
|
| Coombs Test | 1 | 1999 | 8 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1989 | 2585 | 0.010 |
Why?
|
| Forced Expiratory Volume | 1 | 2000 | 136 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 688 | 0.010 |
Why?
|
| Pilot Projects | 2 | 1994 | 917 | 0.010 |
Why?
|
| Hemolysis | 1 | 1999 | 62 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 1999 | 88 | 0.010 |
Why?
|
| Platelet Count | 1 | 1999 | 90 | 0.010 |
Why?
|
| Isoantibodies | 1 | 1999 | 127 | 0.010 |
Why?
|
| Antibodies | 1 | 1999 | 348 | 0.010 |
Why?
|
| Thorax | 1 | 1997 | 78 | 0.010 |
Why?
|
| Isotretinoin | 1 | 1997 | 20 | 0.010 |
Why?
|
| Antidotes | 1 | 1997 | 24 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1998 | 579 | 0.010 |
Why?
|
| Leukopenia | 1 | 1997 | 64 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1999 | 319 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1997 | 131 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1997 | 315 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2003 | 1275 | 0.010 |
Why?
|
| Incidence | 1 | 2000 | 1701 | 0.010 |
Why?
|
| Age Factors | 1 | 2000 | 1906 | 0.010 |
Why?
|
| Esophagogastric Junction | 1 | 1995 | 35 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 1999 | 1799 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 1996 | 158 | 0.010 |
Why?
|
| Cyclohexenes | 1 | 1994 | 5 | 0.010 |
Why?
|
| Benzofurans | 1 | 1994 | 9 | 0.010 |
Why?
|
| Palliative Care | 1 | 1996 | 269 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 1994 | 77 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1995 | 314 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 1995 | 189 | 0.010 |
Why?
|
| Postoperative Care | 1 | 1995 | 235 | 0.010 |
Why?
|
| Research Design | 1 | 1997 | 617 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1994 | 148 | 0.010 |
Why?
|
| Procarbazine | 1 | 1992 | 26 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 1994 | 176 | 0.010 |
Why?
|
| Vincristine | 1 | 1990 | 99 | 0.000 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1994 | 920 | 0.000 |
Why?
|
| Bleomycin | 1 | 1990 | 99 | 0.000 |
Why?
|
| Chi-Square Distribution | 1 | 1990 | 356 | 0.000 |
Why?
|
| Vindesine | 1 | 1989 | 5 | 0.000 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1989 | 44 | 0.000 |
Why?
|
| Mediastinal Neoplasms | 1 | 1989 | 43 | 0.000 |
Why?
|
| Prednisone | 1 | 1990 | 242 | 0.000 |
Why?
|
| Radiography, Abdominal | 1 | 1989 | 63 | 0.000 |
Why?
|
| Cytarabine | 1 | 1990 | 216 | 0.000 |
Why?
|
| Radionuclide Imaging | 1 | 1989 | 189 | 0.000 |
Why?
|
| Thiotepa | 1 | 1989 | 32 | 0.000 |
Why?
|
| Melphalan | 1 | 1989 | 98 | 0.000 |
Why?
|
| Actuarial Analysis | 1 | 1987 | 60 | 0.000 |
Why?
|
| Proportional Hazards Models | 1 | 1990 | 889 | 0.000 |
Why?
|
| Multivariate Analysis | 1 | 1990 | 985 | 0.000 |
Why?
|
| Karyotyping | 1 | 1987 | 222 | 0.000 |
Why?
|
| Radiography, Thoracic | 1 | 1989 | 327 | 0.000 |
Why?
|
| Preoperative Care | 1 | 1989 | 406 | 0.000 |
Why?
|
| Acute Disease | 1 | 1987 | 841 | 0.000 |
Why?
|